# AprilBio Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aprilbio-co

- Industry: Biotechnology
- Headquarters: Chuncheon, South Korea
- Website: www.aprilbio.com
- Total disclosed funding: $49M
- Latest round: Series C (Aug 24, 2021)
- Investors on record: 16

## About

Based in Chuncheon, South Korea, AprilBio Co.,Ltd. focuses on developing innovative therapeutics through its proprietary SAFA™ platform, targeting autoimmune diseases and cancer with enhanced efficacy. AprilBio Co.,Ltd. was founded in 2013 in Chuncheon, South Korea. The company specializes in the development of antibody fragment-based drugs. In July 2022, AprilBio raised KRW 20.7 billion through an IPO, selling 1.29 million shares at KRW 16,000 each, below the expected KRW 20,000-23,000 range. The total amount raised by the company stands at KRW 20.7 billion. The company has completed 7 deals to date.AprilBio specializes in the development of innovative therapeutics utilizing its proprietary SAFA™ platform, which incorporates an anti-serum albumin Fab associated technology. Their core offerings include antibody fragment-based drugs aimed at treating autoimmune diseases and cancer, focusing on enhancing efficacy while minimizing side effects. By leveraging its unique technology, the company seeks to improve the pharmacokinetics of its therapies. The primary customers for AprilBio's products are healthcare providers and pharmaceutical companies in the immunology and oncology fields, targeting global markets, including the United States and Europe. Current development efforts are directed towards specific candidates, such as APB-A1 and APB-R3, which are in various stages of clinical trials to address unmet medical needs.In the most recent financial year, AprilBio reported a revenue of KRW 20,186,405.4 and an EBITDA of KRW 12,376,987.7. The company’s revenue model is centered around partnerships and licensing agreements with pharmaceutical companies and research institutions, focusing on the commercialization of its proprietary drug candidates. Revenues are generated through upfront fees, milestone payments, and royalties on future sales of these products, emphasizing long-term collaborations for effective market entry.AprilBio plans to utilize the funds raised in its recent IPO to support the development of upcoming products and expand its market presence. The company is focused on launching new therapeutic candidates, with specific timelines for upcoming releases as they progress through clinical trials. Additionally, AprilBio aims to expand into new geographic regions, specifically targeting markets in North America and Europe by 2025, enhancing its global footprint. The recent funding will allow the company to strengthen its clinical development and operational capabilities to successfully introduce its innovative therapies.

## Funding rounds

- Series C, Aug 24, 2021, $21M — LB Investment, WOORI Venture Partners, Premier Partners, NH Investment & Securities, LS Securities, Hana Securities, DS Asset Management
- Series B, Nov 30, 2020, $16M — LB Investment, Daekyo Investment, SJ Investment Partners, T.S. Investment, Hana Securities, SM-Sino Technology Investment, BSK Investment, Yuhan Corporation
- Series B, May 31, 2018, $7M — Daekyo Investment, SJ Investment Partners, Wooshin Venture Capital, T.S. Investment, BSK Investment, Mirae Equity Partners
- Series A, May 24, 2017, $2.7M — Kolon Investment, Wooshin Venture Capital, LS Securities, SM-Sino Technology Investment
- Seed, Dec 7, 2016, $1.9M — SM-Sino Technology Investment

## Investors

- SM-Sino Technology Investment (https://capitalatlas.ai/funds/sm-sino-technology-investment) — Seed, Series A, Series B
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series A, Series B
- LS Securities — Series A, Series C
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- SJ Investment Partners (https://capitalatlas.ai/funds/sj-investment-partners) — Series B
- T.S. Investment (https://capitalatlas.ai/funds/t-s-investment) — Series B
- BSK Investment (https://capitalatlas.ai/funds/bsk-investment) — Series B
- Mirae Equity Partners (https://capitalatlas.ai/funds/mirae-equity-partners) — Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series B, Series C
- Hana Securities (https://capitalatlas.ai/funds/hana-securities) — Series B, Series C
- Yuhan Corporation — Series B
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series C
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series C
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series C
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series C